Investing in biotechnology stocks

Understanding the biotech industry

The field of biotechnology focuses on using living organisms or their components to develop innovative products and technologies that improve human health. This includes areas such as pharmaceuticals, medical devices, diagnostics, genetic engineering and agricultural advancements.

When considering investments in the biotech industry, it is important to understand that this sector is highly influenced by scientific breakthroughs, regulatory approvals and market dynamics. The success of a biotech company often hinges on the successful development and commercialisation of its products.

It's essential to stay informed about ongoing clinical trials, FDA approvals and other key developments within the biotech industry. Conducting thorough due diligence on individual companies is crucial before making any investment decisions.

Additionally, it's important to note that investing in the biotech industry can be volatile due to factors such as clinical trial failures, regulatory setbacks or changes in healthcare policies.

Example of biotech stocks

Here are the largest biotech companies based on market capitalisation (as of January 2024):

1. Novo Nordisk (NVO:NYSE): Novo Nordisk is a global healthcare company specialising in diabetes care. It has also gained momentum lately thanks to its weight loss drug Ozempic. With a strong focus on research, development, and production of innovative treatments for diabetes and other chronic diseases, Novo Nordisk has established itself as a leader in the industry. They are committed to improving the lives of millions of people worldwide through their groundbreaking therapies.
2. Vertex Pharmaceuticals (VRTX:NASDAQ): Vertex Pharmaceuticals is a biotechnology company that focuses on developing transformative therapies for serious diseases, such as cystic fibrosis. Their cutting-edge research has led to significant advancements in treatment options for patients suffering from these conditions. Vertex Pharmaceuticals' commitment to scientific excellence has made them a key player in the biopharmaceutical industry.
3. Regeneron Pharmaceuticals (REGN:NASDAQ): Regeneron Pharmaceuticals is a leading biotechnology company known for its innovative approach to drug discovery and development. They have a diverse portfolio of medicines that address various diseases, including oncology, ophthalmology and immunology. Regeneron Pharmaceuticals' dedication to scientific research and collaboration has resulted in groundbreaking therapies that have the potential to improve patient outcomes.
4. Moderna (MRNA:NASDAQ): Moderna is a pioneer in the field of messenger RNA (mRNA) therapeutics. Their groundbreaking technology allows for the development of vaccines and potential treatments for a wide range of diseases, including infectious diseases and rare genetic disorders. Moderna's innovative approach has garnered significant attention within the biotech industry.

Examples of biotech stocks based on their size

1. Large-cap biotech stocks: Large-cap biotech stocks refer to companies with a significant market capitalisation. These companies have established themselves in the industry and often have a track record of success. They are typically well-known names in the biotechnology sector and tend to attract more attention from institutional investors.
   Investing in large-cap biotech stocks can offer certain advantages. These companies have greater financial stability, established revenue streams and robust research pipelines. They often have access to substantial resources for drug development and clinical trials, which increases their chances of bringing successful products to market. Some examples include Moderna, Novo Nordisk and BioNTech SE.
2. Small-cap biotech stocks: On the other hand, small-cap biotech stocks refer to relatively smaller companies with lower market capitalisations. These companies are usually in the early stages of development or have yet to achieve widespread recognition in the industry.
   Investing in small-cap biotech stocks can be riskier but also potentially rewarding. These companies often focus on innovative research and development efforts, which could lead to groundbreaking discoveries and significant growth opportunities. However, they may face challenges such as limited financial resources and higher volatility. Some examples are Alkermes plc and Amylyx Pharmaceuticals, Inc..

Pros & cons of investing in biotech stocks

Pros:

• Potential for high returns: Biotech companies can have the potential to deliver substantial returns on investment. Successful drug approvals or clinical trial results can lead to skyrocketing stock prices, offering investors the chance to earn significant profits.
• Innovation and growth: The biotech industry is known for its constant innovation and groundbreaking discoveries. Companies within this sector are at the forefront of developing new drugs, therapies and technologies that have the potential to revolutionise healthcare.
• Long-term profitability: Many biotech companies focus on finding solutions for chronic diseases such as cancer, Alzheimer's or diabetes. As populations age and these conditions become more prevalent, there is a growing demand for effective treatments.
• Diversification: Investing in biotech stocks allows you to diversify your portfolio beyond traditional industries like finance or technology. This diversification can help spread risk and protect against economic downturns affecting specific sectors.

Cons:

• Volatility: The biotech industry is inherently volatile due to factors such as regulatory hurdles, clinical trial outcomes or patent expirations. A negative outcome or unexpected setback can lead to significant drops in stock prices, causing investors to incur losses.
• High failure rates: Developing new drugs and therapies is a complex and costly process. The majority of biotech companies fail to bring a product to market successfully. Picking the wrong company could result in significant financial losses.
• Regulatory and legal challenges: Biotech companies must navigate complex regulatory processes before their products can reach the market. Delays or rejections by regulatory authorities can impact stock prices negatively.
• Lack of cash flow: Many biotech companies operate at a loss for years while investing heavily in research and development. This lack of consistent cash flow can make it challenging for investors who rely on dividends or regular income from their investments.

Investing in biotech ETFs

If you prefer a diversified approach to investing in the biotech industry, you can consider investing in biotech ETFs. These funds typically hold a basket of biotech stocks, providing exposure to the sector as a whole.

When considering investing in biotech ETFs, it's essential to evaluate factors such as expense ratios, fund performance, holdings and the underlying index or strategy of the ETF. Different biotech ETFs may have varying levels of exposure to specific subsectors within biotechnology, such as pharmaceuticals or medical devices.

Additionally, take into account the overall market conditions and your investment goals before selecting a specific biotech ETF.

It's important to note that investing in biotech ETFs does come with risks. The industry is highly regulated, and there can be significant volatility associated with clinical trial outcomes, regulatory approvals and competition within the sector. It's crucial to conduct thorough research and understand the potential risks before making any investment decisions.

Here are five Biotech ETFs we offer on our platform:

Note: Some ETFs may not be available on our platform for your country (temporarily) due to regulatory reasons.